مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

344
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

164
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Sortilin as a Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia

Pages

  270-276

Abstract

 Background: The overexpression of Sortilin/neurotensin receptor 3 has previously been reported in various human solid tumors but not in hematological malignancies. Here, we report the overexpression of Sortilin in leukemic cells from patients with Chronic Lymphocytic Leukemia (CLL). Methods: Flow cytometry was used to compare the expression of Sortilin in CLL patients (n=52) and healthy individuals (n=26). Also, in vitro Apoptosis induction was assessed in CLL Peripheral Blood Mononuclear Cell (PBMCs) following directly targeting of Sortilin. Results: The results showed a significant expression of Sortilin on the surface of CLL PBMCs (range from 2. 2 to 71. 5%) in comparison to healthy individuals (range from 0. 03 to 7. 4%) (p≤ 0. 0001). The optimal cut-off value of Sortilin expression was determined at 7. 2% with high sensitivity and specificity. Treatment of leukemic cells with anti-Sortilin antibody could induce Apoptosis without any effect on normal cells. Conclusion: Apoptosis induction in CLL cells together with a significant correlation between the expression of Sortilin and CD23 represent a possible functional role of Sortilin in leukemogenesis of CLL cells. Therefore, Sortilin might be considered as a promising novel Biomarker in diagnosis, monitoring, and therapy of patients with CLL.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Farahi, Lia, GHAEMIMANESH, FATEMEH, MILANI, SAEIDEH, RAZAVI, SEYED MOHSEN, AKHONDI, MOHAMMAD MEHDI, & RABBANI, HODJATTALLAH. (2019). Sortilin as a Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), 11(4), 270-276. SID. https://sid.ir/paper/314045/en

    Vancouver: Copy

    Farahi Lia, GHAEMIMANESH FATEMEH, MILANI SAEIDEH, RAZAVI SEYED MOHSEN, AKHONDI MOHAMMAD MEHDI, RABBANI HODJATTALLAH. Sortilin as a Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB)[Internet]. 2019;11(4):270-276. Available from: https://sid.ir/paper/314045/en

    IEEE: Copy

    Lia Farahi, FATEMEH GHAEMIMANESH, SAEIDEH MILANI, SEYED MOHSEN RAZAVI, MOHAMMAD MEHDI AKHONDI, and HODJATTALLAH RABBANI, “Sortilin as a Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia,” AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), vol. 11, no. 4, pp. 270–276, 2019, [Online]. Available: https://sid.ir/paper/314045/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button